IL293429A - Methods and preparations for the treatment of edema resistant to oral diuretics - Google Patents

Methods and preparations for the treatment of edema resistant to oral diuretics

Info

Publication number
IL293429A
IL293429A IL293429A IL29342922A IL293429A IL 293429 A IL293429 A IL 293429A IL 293429 A IL293429 A IL 293429A IL 29342922 A IL29342922 A IL 29342922A IL 293429 A IL293429 A IL 293429A
Authority
IL
Israel
Prior art keywords
bumetanide
pharmaceutical composition
subject
salt
dose
Prior art date
Application number
IL293429A
Other languages
English (en)
Hebrew (he)
Original Assignee
RESQ Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RESQ Pharmaceuticals LLC filed Critical RESQ Pharmaceuticals LLC
Publication of IL293429A publication Critical patent/IL293429A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL293429A 2019-12-04 2020-12-04 Methods and preparations for the treatment of edema resistant to oral diuretics IL293429A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962943638P 2019-12-04 2019-12-04
PCT/US2020/063491 WO2021113775A1 (en) 2019-12-04 2020-12-04 Methods and compositions for treating edema refractory to oral diuretics

Publications (1)

Publication Number Publication Date
IL293429A true IL293429A (en) 2022-07-01

Family

ID=76209409

Family Applications (1)

Application Number Title Priority Date Filing Date
IL293429A IL293429A (en) 2019-12-04 2020-12-04 Methods and preparations for the treatment of edema resistant to oral diuretics

Country Status (10)

Country Link
US (5) US11123319B2 (https=)
EP (1) EP4069222A4 (https=)
JP (1) JP2023505189A (https=)
KR (1) KR20220113436A (https=)
CN (1) CN115023223A (https=)
AU (1) AU2020397176A1 (https=)
BR (1) BR112022010879A2 (https=)
CA (1) CA3160278A1 (https=)
IL (1) IL293429A (https=)
WO (1) WO2021113775A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL293429A (en) 2019-12-04 2022-07-01 RESQ Pharmaceuticals LLC Methods and preparations for the treatment of edema resistant to oral diuretics
JP2024520788A (ja) * 2021-06-09 2024-05-24 レスク ファーマシューティカルズ エルエルシー 経口利尿薬に不応性の浮腫を処置するための皮下製剤及び方法
CA3225946A1 (en) 2021-07-16 2023-01-19 Hubert Clemens Pellikaan Aqueous bumetanide-containing liquid
AU2022425382A1 (en) * 2021-12-30 2024-07-11 Neuropro Therapeutics, Inc. Pharmaceutical composition
CN115645363B (zh) * 2022-10-31 2025-06-10 浙江普利药业有限公司 一种布美他尼注射液及其制备方法
WO2026017600A1 (en) 2024-07-15 2026-01-22 Dripel B.V. Aqueous bumetanide-containing liquid

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
EP2389371A4 (en) * 2009-01-22 2012-09-12 Neurotherapeutics Pharma Inc ANALOGUES OF BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE AND TORSEMID, AND RELATED COMPOSITIONS AND METHODS OF USE
LT2523661T (lt) * 2010-01-15 2017-08-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Nkcc inhibitoriai autizmo gydymui
DK2701684T3 (en) * 2011-04-28 2017-09-18 Platform Brightworks Two Ltd Improved parenteral formulations of lipophilic pharmaceuticals and methods for their preparation and use
US20140128469A1 (en) * 2011-05-10 2014-05-08 Concert Pharmaceuticals Inc. Deuterated n-butyl bumetanide
US20150239832A1 (en) * 2012-09-04 2015-08-27 Neuro Pro Therapeutics, Inc. Analogs and prodrugs of loop diuretics, including bumetanide, furosemide and piretanide; compositions and methods of use
WO2015191473A1 (en) * 2014-06-08 2015-12-17 Autotelic Llc Fixed dose combination for pain relief without edema
US20210163406A1 (en) * 2018-04-06 2021-06-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Bumetanide Derivatives for the Therapy of Stroke and Other Neurological Diseases/Disorders Involving NKCCs
IL293429A (en) 2019-12-04 2022-07-01 RESQ Pharmaceuticals LLC Methods and preparations for the treatment of edema resistant to oral diuretics
JP2024520788A (ja) 2021-06-09 2024-05-24 レスク ファーマシューティカルズ エルエルシー 経口利尿薬に不応性の浮腫を処置するための皮下製剤及び方法

Also Published As

Publication number Publication date
JP2023505189A (ja) 2023-02-08
US20250268853A1 (en) 2025-08-28
WO2021113775A8 (en) 2021-07-22
CN115023223A (zh) 2022-09-06
EP4069222A4 (en) 2023-12-27
US20210169833A1 (en) 2021-06-10
WO2021113775A1 (en) 2021-06-10
US11123319B2 (en) 2021-09-21
US20220287996A1 (en) 2022-09-15
US12150923B2 (en) 2024-11-26
US12558330B2 (en) 2026-02-24
KR20220113436A (ko) 2022-08-12
CA3160278A1 (en) 2021-06-10
US12329731B2 (en) 2025-06-17
EP4069222A1 (en) 2022-10-12
AU2020397176A1 (en) 2022-06-30
US20250032436A1 (en) 2025-01-30
BR112022010879A2 (pt) 2022-10-18
US11260038B1 (en) 2022-03-01

Similar Documents

Publication Publication Date Title
US12558330B2 (en) Methods and compositions for treating edema refractory to oral diuretics
AU2020256337B2 (en) Dosing regimens for echinocandin class compounds
TWI815796B (zh) 包含５－膽甾烯－３，２５－二醇３－硫酸酯（２５ｈｃ３ｓ）或其醫藥上可接受之鹽及至少一種環狀寡醣的組成物，以及使用彼等之方法
US6124358A (en) Pharmaceutical composition containing rhein or diacerhein with improved bioavailability
JP6276756B2 (ja) １，１−ジメチルエチル［（１ｓ）−１−｛［（２ｓ，４ｒ）−４−（７−クロロ−４メトキシイソキノリン−１−イルオキシ）−２−（｛（１ｒ，２ｓ）−１−［（シクロプロピルスルホニル）カルバモイル］−２−エテニルシクロプロピル｝カルバモイル）ピロリジン−１−イル］カルボニル｝−２，２−ジメチルプロピル］カルバメートの可溶化カプセル製剤
ES2321912T3 (es) Formulaciones en nanoparticulas de fenofibrato.
JPH0840936A (ja) 経口投与薬物のための製剤
TW200840596A (en) Microemulsion dosage forms of valsartan and methods of making the same
US20240285566A1 (en) Subcutaneous formulation and methods for treating edema refractory to oral diuretics
KR20110046990A (ko) 올메사르탄메독소밀 함유 자가유화 약물전달시스템 조성물 및 이의 제조방법
US9421268B2 (en) Pediatric oral liquid compositions containing nepadutant
HK40080175A (en) Methods and compositions for treating edema refractory to oral diuretics